GlobeNewswire Inc.··Novo Nordisk A/SNovo Nordisk's Awiqli Wins FDA Approval as First Once-Weekly Basal Insulin for Type 2 Diabetes
FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin for type 2 diabetes, launching in US during second half 2026 based on successful ONWARDS trials.
NVOFDA approvalType 2 diabetes